|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Operating expenses (income): | |||||
| Selling, general and administrative expenses | |||||
| Research and development expenses | |||||
| Legal settlement and litigation benefit, net | |||||
| Reorganization items | |||||
| Impairment of property, plant, & equipment and intangibles | |||||
| Total operating expense, net | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Loss on sale of assets | |||||
| Other income (expense), net | |||||
| Investment and interest income | |||||
| Realized gain on debt securities available for sale | |||||
| Investment and interest income | |||||
| Loss before income taxes | |||||
| Income tax expense (benefit) | |||||
| Net loss | |||||
| Less preferred stock dividend | |||||
| Less accrued preferred stock dividend | |||||
| Net loss attributable to common shareholders | |||||
| Other comprehensive (loss) income: | |||||
| Unrealized (loss) gain on debt securities available for sale | |||||
| Total comprehensive loss attributable to common shareholders | |||||
| Net loss per share attributable to common shareholders | |||||
| Basic | |||||
| Diluted | |||||
| Weighted-average number of common shares outstanding | |||||
| Basic | |||||
| Diluted | |||||
Loading...